Clinigen Group signs agreement to divest its UK compounding business for £7.75 million
LONDON, UK: Clinigen Group plc announced the disposal of its non-core UK Specials manufacturing and Aseptic compounding business to Target Healthcare Ltd for a total consideration of up to £7.75 million. The compounding business sourced and manufactured specific unlicensed medicines referred to as ‘specials’ in a range of formulations for supply across the UK market…